{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:05:35Z","timestamp":1772035535241,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T00:00:00Z","timestamp":1532390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s12185-018-2499-y","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T08:55:36Z","timestamp":1532422536000},"page":"70-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Inhibitor development, safety, and efficacy of Advate\u00ae in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan"],"prefix":"10.1007","volume":"109","author":[{"given":"Masashi","family":"Taki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Fukutake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Shima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junki","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morio","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Uchikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Engl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Shirahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,24]]},"reference":[{"key":"2499_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.blre.2013.06.002","volume":"27","author":"M Franchini","year":"2013","unstructured":"Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev. 2013;27:179\u201384.","journal-title":"Blood Rev"},{"issue":"Suppl 2","key":"2499_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2516.2011.02615.x","volume":"17","author":"EC Rodriguez-Merchan","year":"2011","unstructured":"Rodriguez-Merchan EC, Jimenez-Yuste V, Aznar JA, Hedner U, Knobe K, Lee CA, et al. Joint protection in haemophilia. Haemophilia. 2011;17(Suppl 2):1\u201323.","journal-title":"Haemophilia"},{"key":"2499_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2147\/JBM.S50644","volume":"5","author":"S Lobet","year":"2014","unstructured":"Lobet S, Hermans C, Lambert C. Optimal management of hemophilic arthropathy and hematomas. J Blood Med. 2014;5:207\u201318.","journal-title":"J Blood Med."},{"key":"2499_CR4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","volume":"19","author":"A Srivastava","year":"2013","unstructured":"Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1\u201347.","journal-title":"Haemophilia"},{"key":"2499_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1056\/NEJMoa067659","volume":"357","author":"MJ Manco-Johnson","year":"2007","unstructured":"Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535\u201344.","journal-title":"N Engl J Med"},{"key":"2499_CR6","first-page":"314","volume":"12","author":"V Jim\u00e9nez-Yuste","year":"2014","unstructured":"Jim\u00e9nez-Yuste V, Auerswald G, Benson G, Lambert T, Morfini M, Remor E, et al. Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfus. 2014;12:314\u20139.","journal-title":"Blood Transfus"},{"key":"2499_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bjh.14610","volume":"178","author":"A Iorio","year":"2017","unstructured":"Iorio A, Fischer K, Makris M. Large-scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more. Br J Haematol. 2017;178:20\u201331.","journal-title":"Br J Haematol"},{"key":"2499_CR8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.2165\/11207480-000000000-00000","volume":"72","author":"S Dhillon","year":"2012","unstructured":"Dhillon S. Octocog alfa, antihaemophilic factor (recombinant), plasma\/albumin free method (Advate\u00ae): a review of its use in the management of patients with haemophilia A. Drugs. 2012;72:987\u20131007.","journal-title":"Drugs."},{"key":"2499_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s12185-018-2434-2","volume":"108","author":"H Nogami","year":"2018","unstructured":"Nogami K, Takedani H, Shima M, Yoshioka A, Matsushita T, Takamatsu J, et al. Perioperative safety and hemostatic efficacy of Advate\u00ae in patients with hemophilia A in a postmarketing surveillance in Japan. Int J Hematol. 2018;108:22\u20139.","journal-title":"Int J Hematol"},{"key":"2499_CR10","unstructured":"Pharmaceutical administration and regulations in Japan (individual chapters) Chapter 4 Post-marketing surveillance of drugs. http:\/\/www.jpma.or.jp\/english\/parj\/pdf\/2015.pdf ."},{"key":"2499_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","volume":"17","author":"IE Uijl den","year":"2011","unstructured":"den Uijl IE, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia. 2011;17:41\u20134.","journal-title":"Haemophilia"},{"key":"2499_CR12","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1055\/s-0037-1615621","volume":"85","author":"GC White","year":"2001","unstructured":"White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85:560.","journal-title":"Thromb Haemost"},{"key":"2499_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1365-2516.2008.01823.x","volume":"15","author":"M Taki","year":"2009","unstructured":"Taki M, Shirahata A. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan. Haemophilia. 2009;15:78\u201382.","journal-title":"Haemophilia"},{"key":"2499_CR14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2491\/jjsth.24.619","volume":"24","author":"T Fujii","year":"2013","unstructured":"Fujii T, Amano K, Atsumi T, Ishiguro A, Ohira K, Okamoto K, et al. Treatment guideline for hemophilia without inhibitor: 2013 update. Jpn J Thromb Hemost. 2013;24:619\u201339.","journal-title":"Jpn J Thromb Hemost"},{"key":"2499_CR15","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/jth.13711","volume":"15","author":"AS Velzen Van","year":"2017","unstructured":"Van Velzen AS, Eckardt CL, Peters M, Leebeek FWG, Escuriola-Ettingshausen C, Hermans C, et al. Intensity of factor VIII treatment and development of inhibitors in non-severe hemophilia A patients: results of INSIGHT case-control study. J Thromb Haemost. 2017;15:1422\u20139.","journal-title":"J Thromb Haemost"},{"key":"2499_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2516.2006.01338.x","volume":"12","author":"K Peerlinck","year":"2006","unstructured":"Peerlinck K, Hermans C. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. Haemophilia. 2006;12:579\u201390.","journal-title":"Haemophilia"},{"key":"2499_CR17","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/j.1538-7836.2010.03823.x","volume":"8","author":"A Iorio","year":"2010","unstructured":"Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost. 2010;8:1256\u201365.","journal-title":"J Thromb Haemost"},{"key":"2499_CR18","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1160\/TH11-09-0642","volume":"107","author":"G Auerswald","year":"2012","unstructured":"Auerswald G, Thompson AA, Recht M, Brown D, Liesner R, Guzm\u00e1n-Becerra N, et al. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thromb Haemost. 2012;107:1072\u201382.","journal-title":"Thromb Haemost"},{"key":"2499_CR19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2516.2011.02599.x","volume":"17","author":"A Shirahata","year":"2011","unstructured":"Shirahata A, Fukutake K, Higasa S, Mimaya J, Oka T, Shima M, et al. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan. Haemophilia. 2011;17:771\u20136.","journal-title":"Haemophilia"},{"key":"2499_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1365-2516.2006.01201.x","volume":"12","author":"A Gringeri","year":"2006","unstructured":"Gringeri A, Monzini M, Tagariello G, Scaraggi FA, Mannucci PM, et al. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate. Haemophilia. 2006;12:128\u201332.","journal-title":"Haemophilia"}],"updated-by":[{"DOI":"10.1007\/s12185-018-02564-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000}}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-018-2499-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2499-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2499-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T15:28:55Z","timestamp":1720452535000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-018-2499-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,24]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["2499"],"URL":"https:\/\/doi.org\/10.1007\/s12185-018-2499-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,24]]},"assertion":[{"value":"9 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2018","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors would like to correct the errors in the publication of the original article. The correction details are given below:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Masashi Taki has received personal fees from Shire during the conduct of the study; grants and personal fees from CSL Behring outside the submitted work, personal fees from Shire, Bayer, Bioverativ, Chugai, Kaketsuken, Pfizer, and Novo Nordisk outside the submitted work. Katsuyuki Fukutake has received grants and personal fees from Shire outside the submitted work and holds concurrent posts as a professor for the Department of Molecular Genetics of Coagulation Disorders supported by CSL Behring without additional salary; is an advisory committee member of Chugai Pharmaceutical and consultant of Chugai Pharmaceutical; has received research funding from Bayer, Biogen\/Bioverativ, Kaketsuken, Novo Nordisk, and Pfizer; has received honoraria for consulting, speaking or advising from Bayer, Biogen\/Bioverativ, Chugai Pharm.\/Roche, CSL Behring, Japan Blood Products, Kaketsuken, MSD, Novo Nordisk, Octapharma, and Pfizer. Tadashi Matsushita has received personal fees from Shire for the submitted work; grants and personal fees from Bayer, Shire, Novo Nordisk, Kaketsuken, and Biogen-idec outside the submitted work. Keiji Nogami has received grants from Shire and funding for research from Shire, Bayer, Novo Nordisk, Bioverativ, Chugai, and honoraria from Shire, Bayer, Novo Nordisk, Bioverativ, CSL Behring, Chugai outside the submitted work. Midori Shima has received personal fees and grants from Shire, Bayer, Novo Nordisk, CSL Behring, Chugai, and Pfizer; personal fees from Bioverativ and Roche; grants from Kaketsuken outside the submitted work. Akira Yoshioka has received honoraria from Shire, Japan Red Cross, Daiichi Sankyo, and Bayer outside the submitted work. Junki Takamatsu and Akira Shirahata have declared no conflict of interest. Werner Engl, Haruhiko Uchikawa, Hiroshi Takagi, and Morio Arai are full-time employees of Shire; Werner Engl and Morio Arai own Shire stock.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}